Hubbry Logo
Cardiothoracic surgeryCardiothoracic surgeryMain
Open search
Cardiothoracic surgery
Community hub
Cardiothoracic surgery
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Cardiothoracic surgery
Cardiothoracic surgery
from Wikipedia

Cardiothoracic Surgeon
Cardiothoracic surgeon performs an operation.
Occupation
Names
  • Doctor
  • Surgeon
Occupation type
Specialty
Activity sectors
Medicine, Surgery
Description
Education required
Fields of
employment
Hospitals, Clinics

Cardiothoracic (CT) surgery is the field of medicine involved in surgical treatment of organs inside the thoracic cavity — generally treatment of conditions of the heart (heart disease), lungs (lung disease), and other pleural or mediastinal structures.

In most countries, cardiothoracic surgery is further subspecialized into cardiac surgery (involving the heart and the great vessels) and thoracic surgery (involving the lungs, esophagus, thymus, etc.); the exceptions are the United States, Australia, New Zealand, the United Kingdom, India and some European Union countries such as Portugal.[1]

Training

[edit]

A cardiac surgery residency typically comprises anywhere from four to six years (or longer) of training to become a fully qualified surgeon.[2] Cardiac surgery training may be combined with thoracic surgery and/or vascular surgery and called cardiovascular (CV) / cardiothoracic (CT) / cardiovascular thoracic (CVT) surgery. Cardiac surgeons may enter a cardiac surgery residency directly from medical school, or first complete a general surgery residency followed by a fellowship. Cardiac surgeons may further sub-specialize cardiac surgery by doing a fellowship in a variety of topics including pediatric cardiac surgery, cardiac transplantation, adult-acquired heart disease, weak heart issues, and many more problems in the heart.[citation needed]

Australia and New Zealand

[edit]

The highly competitive Surgical Education and Training (SET) program in Cardiothoracic Surgery is six years in duration, usually commencing several years after completing medical school. Training is administered and supervised via a bi-national (Australia and New Zealand) training program. Multiple examinations take place throughout the course of training, culminating in a final fellowship exam in the final year of training. Upon completion of training, surgeons are awarded a Fellowship of the Royal Australasian College of Surgeons (FRACS), denoting that they are qualified specialists. Trainees having completed a training program in General Surgery and have obtained their FRACS will have the option to complete fellowship training in Cardiothoracic Surgery of four years in duration, subject to college approval. It takes around eight to ten years minimum of post-graduate (post-medical school) training to qualify as a cardiothoracic surgeon. Competition for training places and for public (teaching) hospital places is very high currently, leading to concerns regarding workforce planning in Australia.[citation needed]

Canada

[edit]

Historically, cardiac surgeons in Canada completed general surgery followed by a fellowship in CV / CT / CVT. During the 1990s, the Canadian cardiac surgery training programs changed to six-year "direct-entry" programs following medical school. The direct-entry format provides residents with experience related to cardiac surgery they would not receive in a general surgery program (e.g. echocardiography, coronary care unit, cardiac catheterization etc.). Residents in this program will also spend time training in thoracic and vascular surgery. Typically, this is followed by a fellowship in either Adult Cardiac Surgery, Heart Failure/Transplant, Minimally Invasive Cardiac Surgery, Aortic Surgery, Thoracic Surgery, Pediatric Cardiac Surgery or Cardiac ICU. Contemporary Canadian candidates completing general surgery and wishing to pursue cardiac surgery often complete a cardiothoracic surgery fellowship in the United States. The Royal College of Physicians and Surgeons of Canada also provides a three-year cardiac surgery fellowship for qualified general surgeons that is offered at several training sites including the University of Alberta, the University of British Columbia and the University of Toronto.[citation needed]

Thoracic surgery is its own separate 2–3 year fellowship of general or cardiac surgery in Canada.

Cardiac surgery programs in Canada:[citation needed]

United States

[edit]
Surgeon operating

Cardiac surgery training in the United States is combined with general thoracic surgery and called cardiothoracic surgery or thoracic surgery. A cardiothoracic surgeon in the U.S. is a physician who first completes a general surgery residency (typically 5–7 years), followed by a cardiothoracic surgery fellowship (typically 2–3 years). The cardiothoracic surgery fellowship typically spans two or three years, but certification is based on the number of surgeries performed as the operating surgeon, not the time spent in the program, in addition to passing rigorous board certification tests. Two other pathways to shorten the duration of training have been developed: (1) a combined general-thoracic surgery residency consisting of four years of general surgery training and three years of cardiothoracic training at the same institution and (2) an integrated six-year cardiothoracic residency (in place of the general surgery residency plus cardiothoracic residency), which have each been established at many programs (over 20).[3] Applicants match into the integrated six-year (I-6) programs directly out of medical school, and the application process has been extremely competitive for these positions as there were approximately 160 applicants for 10 spots in the U.S. in 2010. As of May 2013, there are 20 approved programs, which include the following:

Integrated six-year Cardiothoracic Surgery programs in the United States:[citation needed]

The American Board of Thoracic Surgery offers a special pathway certificate in congenital cardiac surgery which typically requires an additional year of fellowship. This formal certificate is unique because congenital cardiac surgeons in other countries do not have formal evaluation and recognition of pediatric training by a licensing body.

Cardiac surgery

[edit]
Cardiothoracic surgery
Two cardiac surgeons performing a cardiac surgery known as coronary artery bypass surgery. Note the use of a steel retractor to forcefully maintain the exposure of the patient's heart.
ICD-9-CM3537
MeSHD006348
OPS-301 code5-35...5-37

The earliest operations on the pericardium (the sac that surrounds the heart) took place in the 19th century and were performed by Francisco Romero (1801)[4] Dominique Jean Larrey, Henry Dalton, and Daniel Hale Williams.[5] The first surgery on the heart itself was performed by Norwegian surgeon Axel Cappelen on 4 September 1895 at Rikshospitalet in Kristiania, now Oslo. He ligated a bleeding coronary artery in a 24-year-old man who had been stabbed in the left axilla and was in deep shock upon arrival. Access was through a left thoracotomy. The patient awoke and seemed fine for 24 hours, but became ill with increasing temperature and he ultimately died from what the post mortem proved to be mediastinitis on the third postoperative day.[6][7] The first successful surgery of the heart, performed without any complications, was by Ludwig Rehn of Frankfurt, Germany, who repaired a stab wound to the right ventricle on September 7, 1896.[8][9]

Surgery in great vessels (aortic coarctation repair, Blalock-Taussig shunt creation, closure of patent ductus arteriosus) became common after the turn of the century and falls in the domain of cardiac surgery, but technically cannot be considered heart surgery. One of the more commonly known cardiac surgery procedures is the coronary artery bypass graft (CABG), also known as "bypass surgery."

Early approaches to heart malformations

[edit]

In 1925 operations on the heart valves were unknown. Henry Souttar operated successfully on a young woman with mitral stenosis. He made an opening in the appendage of the left atrium and inserted a finger into this chamber in order to palpate and explore the damaged mitral valve. The patient survived for several years[10] but Souttar's physician colleagues at that time decided the procedure was not justified and he could not continue.[11][12]

Cardiac surgery changed significantly after World War II. In 1948 four surgeons carried out successful operations for mitral stenosis resulting from rheumatic fever. Horace Smithy (1914–1948) revived an operation due to Dr Dwight Harken of the Peter Bent Brigham Hospital using a punch to remove a portion of the mitral valve. Charles Bailey (1910–1993) at the Hahnemann Hospital, Philadelphia, Dwight Harken in Boston and Russell Brock at Guy's Hospital all adopted Souttar's method. All these men started work independently of each other, within a few months. This time Souttar's technique was widely adopted although there were modifications.[11][12]

In 1947 Thomas Holmes Sellors (1902–1987) of the Middlesex Hospital operated on a Fallot's Tetralogy patient with pulmonary stenosis and successfully divided the stenosed pulmonary valve. In 1948, Russell Brock, probably unaware of Sellor's work, used a specially designed dilator in three cases of pulmonary stenosis. Later in 1948 he designed a punch to resect the infundibular muscle stenosis which is often associated with Fallot's Tetralogy. Many thousands of these "blind" operations were performed until the introduction of heart bypass made direct surgery on valves possible.[11]

Open heart surgery

[edit]

Open heart surgery is a procedure in which the patient's heart is opened and surgery is performed on the internal structures of the heart. It was discovered by Wilfred G. Bigelow of the University of Toronto that the repair of intracardiac pathologies was better done with a bloodless and motionless environment, which means that the heart should be stopped and drained of blood. The first successful intracardiac correction of a congenital heart defect using hypothermia was performed by C. Walton Lillehei and F. John Lewis at the University of Minnesota on September 2, 1952. The following year, Soviet surgeon Aleksandr Aleksandrovich Vishnevskiy conducted the first cardiac surgery under local anesthesia.[citation needed]

Surgeons realized the limitations of hypothermia – complex intracardiac repairs take more time and the patient needs blood flow to the body, particularly to the brain. The patient needs the function of the heart and lungs provided by an artificial method, hence the term cardiopulmonary bypass. John Heysham Gibbon at Jefferson Medical School in Philadelphia reported in 1953 the first successful use of extracorporeal circulation by means of an oxygenator, but he abandoned the method, disappointed by subsequent failures. In 1954 Lillehei realized a successful series of operations with the controlled cross-circulation technique in which the patient's mother or father was used as a 'heart-lung machine'. John W. Kirklin at the Mayo Clinic in Rochester, Minnesota started using a Gibbon type pump-oxygenator in a series of successful operations, and was soon followed by surgeons in various parts of the world.[citation needed]

Nazih Zuhdi performed the first total intentional hemodilution open heart surgery on Terry Gene Nix, age 7, on February 25, 1960, at Mercy Hospital, Oklahoma City, OK. The operation was a success; however, Nix died three years later in 1963.[13] In March, 1961, Zuhdi, Carey, and Greer, performed open heart surgery on a child, age 3+12, using the total intentional hemodilution machine. In 1985 Zuhdi performed Oklahoma's first successful heart transplant on Nancy Rogers at Baptist Hospital. The transplant was successful, but Rogers, who had cancer, died from an infection 54 days after surgery.[14]

Modern beating-heart surgery

[edit]

Since the 1990s, surgeons have begun to perform "off-pump bypass surgery" – coronary artery bypass surgery without the aforementioned cardiopulmonary bypass. In these operations, the heart is beating during surgery, but is stabilized to provide an almost still work area in which to connect the conduit vessel that bypasses the blockage; in the U.S., most conduit vessels are harvested endoscopically, using a technique known as endoscopic vessel harvesting (EVH).[citation needed]

Some researchers believe that the off-pump approach results in fewer post-operative complications, such as postperfusion syndrome, and better overall results. Study results are controversial as of 2007, the surgeon's preference and hospital results still play a major role.[citation needed]

Minimally invasive surgery

[edit]

A new form of heart surgery that has grown in popularity is robot-assisted heart surgery. This is where a machine is used to perform surgery while being controlled by the heart surgeon. The main advantage to this is the size of the incision made in the patient. Instead of an incision being at least big enough for the surgeon to put his hands inside, it does not have to be bigger than "pencil-sized" holes for the robot's much smaller "hands" to enter a surgical patient's body.[15]

In September 2024, the first successful fully robotic heart transplant took place at King Faisal Specialist Hospital and Research Centre in Riyadh, led by surgeon Feras Khaliel, head of the hospital's cardiac surgery and director of its Robotics and Minimally Invasive Surgery Program.[16] In December 2024, the first robotic surgery for a combined robotic aortic valve replacement (AVR) and coronary artery bypass grafting (CABG) was successfully performed through one small incision at West Virginia University, led by surgeon Vinay Badhwar, who is the executive chair of the WVU Heart and Vascular Institute and a vice president of the Society of Thoracic Surgeons.[17][18]

Pediatric cardiovascular surgery

[edit]

Pediatric cardiovascular surgery is surgery of the heart of children. The first operations to repair cardio-vascular[19] defects in children were performed by Clarence Crafoord in Sweden when he repaired coarctation of the aorta in a 12-year-old boy.[20] The first attempts to palliate congenital heart disease were performed by Alfred Blalock with the assistance of William Longmire, Denton Cooley, and Blalock's experienced technician, Vivien Thomas in 1944 at Johns Hopkins Hospital.[21] Techniques for repair of congenital heart defects without the use of a bypass machine were developed in the late 1940s and early 1950s. Among them was an open repair of an atrial septal defect using hypothermia, inflow occlusion and direct vision in a 5-year-old child performed in 1952 by Lewis and Lillihei. Lillihei used cross-circulation between a boy and his father to maintain perfusion while performing a direct repair of a ventricular septal defect in a 4-year-old child in 1954.[22] He continued to use cross-circulation and performed the first corrections of tetralogy of Fallot and presented those results in 1955 at the American Surgical Association. In the long-run, pediatric cardiovascular surgery would rely on the cardiopulmonary bypass machine developed by Gibbon and Lillehei as noted above.[citation needed]

Risks of cardiac surgery

[edit]

The development of cardiac surgery and cardiopulmonary bypass techniques has reduced the mortality rates of these surgeries to relatively low ranks. For instance, repairs of congenital heart defects are currently estimated to have 4–6% mortality rates.[23][24] A major concern with cardiac surgery is the incidence of neurological damage. Stroke occurs in 5% of all people undergoing cardiac surgery, and is higher in patients at risk for stroke.[25] A more subtle constellation of neurocognitive deficits attributed to cardiopulmonary bypass is known as postperfusion syndrome, sometimes called "pumphead". The symptoms of postperfusion syndrome were initially felt to be permanent,[26] but were shown to be transient with no permanent neurological impairment.[27]

To assess the performance of surgical units and individual surgeons, a popular risk model has been created called the EuroSCORE. This takes a number of health factors from a patient and using precalculated logistic regression coefficients attempts to give a percentage chance of survival to discharge. Within the UK this EuroSCORE was used to give a breakdown of all the centres for cardiothoracic surgery and to give some indication of whether the units and their individual surgeons performed within an acceptable range. The results are available on the CQC website.[28] The precise methodology used has however not been published to date nor has the raw data on which the results are based.[citation needed]

Infection represents the primary non-cardiac complication from cardiothoracic surgery. Infections include mediastinitis, infectious myo- or pericarditis, endocarditis, cardiac device infection, pneumonia, empyema, and bloodstream infections. Clostridioides difficile colitis can develop when prophylactic or post-operative antibiotics are used.

Post-operative patients of cardiothoracic surgery are at risk of nausea, vomiting, dysphagia, and aspiration pneumonia.[29]

Thoracic surgery

[edit]

A pleurectomy is a surgical procedure in which part of the pleura is removed. It is sometimes used in the treatment of pneumothorax and mesothelioma.[30] In case of pneumothorax, only the apical and the diaphragmatic portions of the parietal pleura are removed.[citation needed]

Lung volume reduction surgery

[edit]

Lung volume reduction surgery, or LVRS, can improve the quality of life for certain patients with COPD of emphysematous type, when other treatment options are not enough. Parts of the lung that are particularly damaged by emphysema are removed, allowing the remaining, relatively good lung to expand and work more efficiently. The beneficial effects are correlated with the achieved reduction in residual volume.[31] Conventional LVRS involves resection of the most severely affected areas of emphysematous, non-bullous lung (aim is for 20–30%). This is a surgical option involving a mini-thoracotomy for patients in end stage COPD due to underlying emphysema, and can improve lung elastic recoil as well as diaphragmatic function.[citation needed]

The National Emphysema Treatment Trial (NETT) was a large multicentre study (N = 1218) comparing LVRS with non-surgical treatment. Results suggested that there was no overall survival advantage in the LVRS group, except for mainly upper-lobe emphysema + poor exercise capacity, and significant improvements were seen in exercise capacity in the LVRS group.[32] Later studies have shown a wider scope of treatment with better outcomes.[33]

Possible complications of LVRS include prolonged air leak (mean duration post surgery until all chest tubes removed is 10.9 ± 8.0 days.[34]

In people who have a predominantly upper lobe emphysema, lung volume reduction surgery could result in better health status and lung function, though it also increases the risk of early mortality and adverse events.[35]

LVRS is used widely in Europe, though its application in the United States is mostly experimental.[36]

A less invasive treatment is available as a bronchoscopic lung volume reduction procedure.[37]

Lung cancer surgery

[edit]

Not all lung cancers are suitable for surgery. The stage, location and cell type are important limiting factors. In addition, people who are very ill with a poor performance status or who have inadequate pulmonary reserve would be unlikely to survive. Even with careful selection, the overall operative death rate is about 4.4%.[38]

In non-small cell lung cancer staging, stages IA, IB, IIA, and IIB are suitable for surgical resection.[39]

Pulmonary reserve is measured by spirometry. If there is no evidence of undue shortness of breath or diffuse parenchymal lung disease, and the FEV1 exceeds 2 litres or 80% of predicted, the person is fit for pneumonectomy. If the FEV1 exceeds 1.5 litres, the patient is fit for lobectomy.[40]

There is weak evidence to indicate that participation in exercise programs before lung cancer surgery may reduce the risk of complications after surgery.[41]

Complications

[edit]

A prolonged air leak (PAL) can occur in 8–25% of people following lung cancer surgery.[42][43] This complication delays chest tube removal and is associated with an increased length of hospital stay following a lung resection (lung cancer surgery).[44][45] The use of surgical sealants may reduce the incidence of prolonged air leaks, however, this intervention alone has not been shown to results in a decreased length of hospital stay following lung cancer surgery.[46]

There is no strong evidence to support using non-invasive positive pressure ventilation following lung cancer surgery to reduce pulmonary complications.[47]

Types

[edit]
  • Lobectomy (removal of a lobe of the lung)[48]
  • Sublobar resection (removal of part of lobe of the lung)
  • Segmentectomy (removal of an anatomic division of a particular lobe of the lung)
  • Pneumonectomy (removal of an entire lung)
  • Wedge resection
  • Sleeve/bronchoplastic resection (removal of an associated tubular section of the associated main bronchial passage during lobectomy with subsequent reconstruction of the bronchial passage)
  • VATS lobectomy (minimally invasive approach to lobectomy that may allow for diminished pain, quicker return to full activity, and diminished hospital costs)[49][50]
  • esophagectomy (removal of the esophagus)

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Cardiothoracic surgery is a surgical specialty dedicated to the diagnosis, treatment, and management of diseases affecting the organs and structures within the thorax, including the heart, lungs, esophagus, trachea, and major blood vessels such as the thoracic aorta. This field combines elements of cardiac surgery, which focuses on the heart and great vessels, and thoracic surgery, which addresses the lungs, pleura, and mediastinum. Cardiothoracic surgeons employ a range of techniques, from open procedures to minimally invasive and robotic-assisted methods, to treat conditions such as coronary artery disease, valvular heart disease, lung cancer, and esophageal disorders. The history of cardiothoracic surgery spans over a century, marked by groundbreaking innovations that transformed it from a high-risk endeavor into a cornerstone of modern . Early milestones include ' successful repair of a to the heart in , recognized as one of the first cardiac surgeries. The field advanced significantly in the mid-20th century with the invention of the machine by in 1953, enabling open-heart procedures like valve repairs and congenital defect corrections. Subsequent developments, including coronary bypass grafting (CABG) pioneered in the , further expanded treatment options for ischemic heart disease. Today, the specialty continues to evolve, with volumes of cardiac surgeries stabilizing post-pandemic and increasing by 4.2% from 2022 to 2023. Common procedures in cardiothoracic surgery reflect its dual focus on cardiac and thoracic pathologies. In , prevalent interventions include CABG to restore blood flow in blocked , heart valve repair or replacement for conditions like , and for end-stage . Thoracic procedures often involve (VATS) for lung resections in cancer cases, lobectomies, and esophageal surgeries such as esophagectomy for tumors. These operations are performed by highly trained specialists who prioritize patient outcomes, with databases like the Society of Thoracic Surgeons (STS) National Database tracking quality metrics for adult cardiac, general thoracic, and congenital heart surgery. Training to become a cardiothoracic surgeon is rigorous and follows structured pathways approved by bodies like the American Board of Thoracic Surgery (ABTS) and Accreditation Council for Graduate Medical Education (ACGME). The traditional route requires completion of a 5-year residency followed by a 2- to 3-year cardiothoracic surgery fellowship, totaling 7-8 years of postgraduate . Alternatively, integrated (I-6) programs offer 6 years of combined directly after , emphasizing early exposure to complex cases. Recent advances, including robotic surgery, for preoperative planning, and enhanced recovery after surgery (ERAS) protocols, are increasingly incorporated into to prepare surgeons for innovative, patient-centered care.

Overview

Definition and Scope

Cardiothoracic surgery is a specialized field of medicine dedicated to the surgical treatment of diseases and conditions affecting the organs within the thorax, including the heart, lungs, esophagus, great blood vessels, diaphragm, and chest wall. This specialty combines elements of cardiac surgery, which focuses on the heart and its associated vessels, and thoracic surgery, which addresses the lungs, airways, and other chest structures. In the United States, training and certification for cardiothoracic surgery are governed by the American Board of Thoracic Surgery, encompassing both cardiac and thoracic components in a unified pathway. The scope of cardiothoracic surgery is distinct from related fields such as , which primarily manages diseases of the arterial and venous systems outside the and heart, such as and issues, and , which broadly covers abdominal, endocrine, and trauma procedures but excludes specialized thoracic interventions. Cardiothoracic procedures range from elective operations, like coronary artery bypass grafting for or for , to emergency interventions for thoracic trauma or acute aortic dissections. These surgeries often require advanced techniques, including the use of for cardiac cases or video-assisted thoracoscopy for pulmonary conditions. Cardiothoracic surgeons play a critical role in managing patients across the lifespan, from neonates with congenital heart defects requiring repairs like closure to elderly adults undergoing valve replacements for degenerative conditions. The field addresses a wide array of pathologies, including acquired heart diseases, malignancies of the and , and traumatic injuries to thoracic structures, often in multidisciplinary settings with cardiologists, pulmonologists, and oncologists. This comprehensive approach ensures holistic care for complex thoracic disorders.

Multidisciplinary Integration

Cardiothoracic surgery relies on a multidisciplinary framework that integrates expertise from various medical specialties to optimize patient outcomes, particularly in complex cases involving the heart, lungs, and thoracic vasculature. The heart team model exemplifies this collaboration, bringing together surgeons, interventional cardiologists, and imaging specialists to evaluate treatment options through shared decision-making and comprehensive assessments. This approach ensures that surgical interventions are informed by a holistic understanding of the patient's condition, reducing risks and improving procedural success rates. Integration with cardiology is fundamental for preoperative diagnostics, where cardiologists perform critical imaging studies such as to assess cardiac structure and function, and to evaluate vascular anatomy and blockages. provides real-time visualization of valvular function and , guiding surgical planning for procedures like valve repair or replacement, while identifies severity, informing decisions on strategies. These diagnostic tools, often conducted in multidisciplinary conferences, facilitate precise risk stratification and personalized treatment pathways. Collaboration with enhances preoperative evaluation and perioperative respiratory management, especially in thoracic procedures where resection or compromised ventilation is anticipated. Pulmonologists conduct pulmonary function tests, including to measure forced expiratory volume and , and (DLCO) to assess efficiency, helping to predict postoperative respiratory complications and determine surgical candidacy. In the intraoperative and postoperative phases, pulmonologists contribute to strategies like bronchodilator therapy and ventilator weaning protocols, mitigating risks such as or prolonged in patients with underlying . Anesthesiology plays a pivotal role in managing (CPB) during , where anesthesiologists monitor , administer anticoagulants, and adjust settings to maintain oxygenation while the heart is arrested. During CPB, they oversee lung-protective ventilation strategies, such as low tidal volumes and , to prevent ventilator-induced injury and inflammatory responses triggered by the bypass circuit. Postoperatively, anesthesiologists direct in the , titrating settings based on gases and chest imaging to facilitate early extubation and reduce complications like . Team-based approaches in cardiothoracic intensive care units emphasize coordinated care involving perfusionists and specialized nurses to handle thoracic drainage and hemodynamic stability. Perfusionists, trained in extracorporeal circulation, extend their expertise beyond the operating room to assist in postoperative monitoring of and renal function, collaborating with the surgical team to manage potential complications from CPB. Specialized nurses focus on thoracic drainage systems, regularly assessing output for volume and character to detect issues like or , while providing pain management and mobility support to promote recovery. This interdisciplinary model, as outlined in enhanced recovery after (ERAS) protocols, has been associated with shorter hospital stays and lower readmission rates through standardized, evidence-based interventions.

History

Early Thoracic Surgery

Early thoracic surgery emerged in the 19th century primarily through diagnostic and therapeutic interventions for pleural conditions, such as , which involves aspirating fluid from the pleural space to relieve effusions. This procedure, though rooted in ancient practices, saw its modern development with the first successful performance by American physician Morrill Wyman in 1850, followed by a detailed description by Henry Ingersoll Bowditch in 1852, who advocated its use for tuberculous and emphasized safer needle techniques to reduce risks like pneumothorax.00342-4/fulltext) Initial efforts focused on managing and effusions, but operative interventions on the lung itself remained rudimentary due to limited understanding of pulmonary physiology and high operative mortality exceeding 90% in early resection attempts.30361-1/fulltext) By the early , advancements in surgical technique enabled more ambitious resections for conditions like bronchiectasis and . A pivotal milestone was Harold Brunn's 1929 description of the first successful one-stage , performed in a free pleural space with complete closure of the chest wall using drainage, which demonstrated improved survival by addressing issues like bronchial stump management and infection control.01114-1/fulltext) This approach marked a shift from multi-stage procedures to single operations, influencing subsequent thoracic resections. Four years later, in 1933, Evarts A. Graham achieved the first successful one-stage for , removing the entire left from James Gilmore, who survived 30 years post-operation; this procedure established the feasibility of total lung excision and spurred global interest in pulmonary .00692-1/fulltext) Significant challenges in early thoracic surgery included rampant postoperative infections and inadequate anesthesia, which often led to respiratory collapse during open-chest procedures. The introduction of penicillin in the 1940s revolutionized infection control, drastically reducing empyema rates from over 50% in pre-antibiotic eras to under 5% in controlled series, enabling safer elective resections.30361-1/fulltext) Concurrently, improvements in anesthesia, such as the adoption of endotracheal intubation and positive-pressure ventilation in the 1910s–1920s by pioneers like Ivan Magill, allowed better airway management and oxygenation, mitigating the "shock lung" phenomenon and expanding the scope of intrathoracic operations. These developments laid the groundwork for thoracic surgery's maturation, with Brunn and Graham exemplifying the innovative spirit that overcame physiological barriers to chest cavity interventions.01114-1/fulltext)

Advances in Cardiac Surgery

One of the earliest significant advances in cardiac surgery was the development of the Blalock-Taussig shunt in , a palliative procedure for infants with and other cyanotic congenital heart defects. This surgery, performed by surgeon and pediatric cardiologist Helen Taussig at , involved anastomosing the to the to increase pulmonary blood flow and alleviate . The first successful operation on November 29, , marked a breakthrough in treating previously inoperable congenital conditions, saving the life of a 15-month-old patient and paving the way for further innovations in pediatric cardiac repair. A pivotal technological milestone came in 1953 with the invention of the heart-lung machine by Jr., which allowed for the first successful open-heart surgery under direct vision. Gibbon's extracorporeal device oxygenated and circulated blood, bypassing the heart and lungs during procedures, and was used on May 6, 1953, to repair an in an 18-year-old patient at Jefferson Hospital in . This innovation transformed from indirect, closed-heart techniques to precise intracardiac interventions, enabling complex repairs that were previously impossible. In 1960, the introduction of the first prosthetic heart valve by surgeon Albert Starr and engineer Lowell Edwards represented another landmark advancement, addressing through mechanical replacement. The Starr-Edwards ball-and-cage valve, implanted successfully in a patient's mitral position at the , utilized a ball within a metal cage to mimic natural valve function, with the initial procedure lasting over an hour and resulting in patient survival. This , refined through iterative animal and human trials, became a standard for and has been implanted in hundreds of thousands of patients worldwide, significantly improving outcomes for those with severe regurgitation or . The field advanced further with the first coronary artery bypass graft (CABG) procedure in 1967, pioneered by at the . On May 9, 1967, Favaloro performed a saphenous vein graft from the to the in a 51-year-old woman with proximal occlusion, restoring blood flow to ischemic myocardium without interrupting native circulation. This technique, building on prior methods, revolutionized treatment for by providing durable , and its adoption led to widespread use in managing and preventing .

Evolution of the Field

The formal recognition of cardiothoracic surgery as a distinct specialty emerged in the mid-20th century, building on the foundational efforts of organizations like the American Board of Thoracic Surgery (ABTS). Established in 1948 as the Board of Thoracic Surgery under the auspices of the American Board of Surgery, the ABTS initially focused on certifying surgeons in thoracic procedures but expanded its scope post-World War II to encompass cardiac interventions, reflecting the rapid advancements in open-heart surgery during the . This certification process solidified cardiothoracic surgery's status as a unified field, separate from , by standardizing qualifications and promoting specialized expertise in both cardiac and thoracic domains.31040-9/fulltext) By the late , training paradigms evolved to address the growing complexity of the specialty, shifting from separate cardiac and thoracic pathways to integrated programs. Discussions on integrated training began in the , particularly in regions like , where task forces recommended streamlined curricula to better prepare surgeons for comprehensive cardiothoracic practice.01742-X/fulltext) In the United States, this culminated in the approval of the first Accreditation Council for Graduate Medical Education (ACGME)-recognized 6-year integrated cardiothoracic surgery residencies in , marking a formal transition from the traditional 5- or 6-year residency followed by 2- or 3-year fellowships. This integration aimed to foster early exposure to both cardiac and thoracic procedures, enhancing technical proficiency and interdisciplinary collaboration. Advancements in imaging technologies profoundly influenced surgical planning and outcomes in cardiothoracic surgery from the 1970s onward. The introduction of computed tomography (CT) in the early 1970s provided initial cross-sectional visualization of thoracic structures, but the development of multidetector CT angiography in the 1990s revolutionized preoperative assessment by enabling non-invasive, high-resolution mapping of , aortic , and pulmonary vasculature. These tools reduced the reliance on , improved risk stratification, and facilitated minimally invasive techniques, with studies demonstrating enhanced accuracy in diagnosing congenital defects and planning procedures. Global standardization efforts further propelled the field's evolution, exemplified by the founding of the European Association for Cardio-Thoracic Surgery (EACTS) in 1986. Established by a group of visionary surgeons to unify professional standards across , the EACTS promoted collaborative , guideline development, and educational initiatives that bridged national variations in practice. Its growth into a multinational body with nearly 4,000 members has supported evidence-based protocols for both cardiac and thoracic interventions, fostering international consensus on training and ethical standards.

Training and Practice

North American Pathways

In , training pathways for cardiothoracic surgery emphasize rigorous following , with structures designed to produce surgeons proficient in both cardiac and thoracic procedures. In the United States, the Accreditation Council for Graduate Medical Education (ACGME) accredits three primary pathways for cardiothoracic surgery residency: the integrated 6-year pathway (I-6), the traditional independent pathway, and the joint /thoracic surgery (4+3) pathway. The integrated 6-year pathway (I-6) begins directly after and combines foundational training in principles with progressive specialization in cardiothoracic surgery, typically allocating the first three years to broad surgical exposure and the latter three to advanced cardiothoracic rotations. This model, approved by ACGME in 2007, aims to streamline training and attract candidates earlier in their careers by providing dedicated cardiothoracic experience from the outset. The traditional pathway, in contrast, requires completion of a 5-year ACGME-accredited residency followed by a 3-year independent cardiothoracic surgery residency, allowing trainees to gain comprehensive general surgical expertise before subspecializing. The 4+3 pathway is a seven-year program that integrates four years of with three years of thoracic surgery, leading to dual by the American Board of Surgery and the American Board of Thoracic Surgery. This route, which has been the standard since the mid-20th century, accommodates physicians who may pursue general surgery independently and offers flexibility for those interested in broader surgical practice. Both pathways culminate in eligibility for by the American Board of Thoracic Surgery (ABTS), which administers qualifying examinations assessing clinical knowledge, operative skills, and professional competencies. In Canada, the Royal College of Physicians and Surgeons of (RCPSC) oversees training, with pathways mirroring U.S. structures but tailored to the national healthcare system and emphasizing in either or thoracic surgery as distinct yet overlapping specialties. For , candidates may enter a 6-year direct-entry residency program post-medical school, integrating foundational surgical training with specialized cardiac rotations, or a 3-year residency following completion of a 5-year program. Thoracic surgery training requires prior RCPSC in or , followed by a 2-year residency focused on thoracic procedures, ensuring comprehensive preparation for complex cases. These programs, accredited by the RCPSC, prioritize high-volume clinical exposure and align with CanMEDS competencies for medical expertise and . Board certification in the United States is granted by the ABTS following successful completion of an approved pathway and passing a written qualifying examination, with oral examinations for select candidates; Canadian graduates are eligible via reciprocal recognition of RCPSC certification. Maintenance of certification (MOC) is mandatory every 10 years for ABTS diplomates, involving periodic assessments, continuing medical education, and practice improvement activities to ensure ongoing competence. Similarly, RCPSC certification requires and periodic recertification to uphold standards in evolving cardiothoracic practices.

Asia-Pacific and Oceanic Training

In the Asia-Pacific and Oceanic region, particularly and , cardiothoracic surgery training is coordinated by the Royal Australasian College of Surgeons (RACS) through its Surgical Education and Training (SET) program, which spans 6 years following graduation. This duration includes an initial foundational year (SET 1) focused on general surgical skills, followed by 5 years (SET 2-6) of specialized cardiothoracic experience, encompassing both cardiac and thoracic procedures to produce independent practitioners in these areas. The SET program emphasizes progressive operative competence, with trainees required to maintain a of cases recorded via the Morbidity Audit and Tool (MALT), which is mandatory for all levels and reviewed semiannually by the Cardiothoracic Surgery Education and Training Committee. To achieve certification, trainees must meet the minimum operative experience criteria set by the RACS Board of Cardiothoracic Surgery, including a specified number of major cases as primary operator across cardiac and thoracic domains (as defined in current RACS guidelines). This operative threshold ensures comprehensive exposure, with the program sharing structural similarities to North American pathways in its residency-based format but tailored to regional healthcare needs. Training rotations incorporate an emphasis on rural and indigenous health, aligning with RACS's broader initiatives to address disparities in surgical access for Aboriginal, Torres Strait Islander, and populations, including dedicated scholarships and selection pathways that encourage rotations in underserved areas. Upon successful completion of the SET program, including examinations and assessments, trainees are awarded Fellowship of the Royal Australasian College of Surgeons (FRACS) in Cardiothoracic Surgery, granting specialist registration in and . Certified fellows must then engage in ongoing Continuing Professional Development (CPD) activities, such as annual audits and educational modules, to maintain their status and ensure .

European and Global Variations

In , cardiothoracic surgery training is overseen by the European Board of Cardio-Thoracic Surgery (EBCTS), under the Union Européenne des Médecins Spécialistes (UEMS), which establishes pan-European standards for certification through a two-part examination process: the Membership (Part 1, theoretical) and Fellowship (Part 2, oral and clinical). Training programs typically last 6 years following basic surgical residency, emphasizing competency-based progression in cardiac, thoracic, and vascular procedures, though national variations exist. For instance, in the , the Joint Committee on Surgical Training (JCST) administers an outcome-based higher specialty training program with an indicative duration of 7 years from the start of , focusing on operative logs, assessments, and the Intercollegiate Specialty Examination. Subspecialty fellowships in often follow core training, providing advanced expertise in areas such as congenital or heart and . The European Association for Cardio-Thoracic Surgery (EACTS) supports these through targeted programs like the Francis Fontan Fund fellowships, which offer 6- to 12-month placements in high-volume centers for skills in pediatric cardiac repair or transplant management. These fellowships prioritize hands-on experience and international mobility to address subspecialty gaps, with potentially integrated via EBCTS Level 2 outcomes. Globally, training adapts to resource constraints, particularly in low- and middle-income countries, where programs are often shorter to address workforce shortages. In , the National Board of Examinations in Medical Sciences (NBEMS) offers a 3-year (DNB) in cardiothoracic and following a 3-year (MS) in , or alternatively a direct 6-year Doctor of National Board (DrNB) pathway post-MBBS, emphasizing essential procedures like coronary artery bypass grafting in under-resourced settings. This model contrasts with longer European durations by focusing on practical competency in high-burden diseases, though it may limit exposure to advanced techniques. Harmonization efforts are advanced by international societies such as the Society of Thoracic Surgeons (STS) and EACTS, which collaborate on standards through joint guidelines and mutual recognition initiatives to facilitate global mobility and uniform quality. For example, their combined methodology for documents ensures aligned benchmarks across continents. These partnerships, including shared educational resources, aim to bridge disparities in while respecting regional adaptations.

Cardiac Surgery

In high-volume tertiary referral practices, expert cardiothoracic surgeons commonly perform mitral and tricuspid valve repair, coronary artery bypass grafting, aortic root and arch surgery, and manage acute aortic dissection as part of a specialized multidisciplinary team.

Coronary Revascularization

Coronary artery bypass grafting (CABG) is a surgical procedure designed to restore blood flow to the myocardium by creating detours around obstructed using autologous conduits. The operation typically involves harvesting vascular grafts, such as the saphenous vein from the leg or the internal mammary (IMA) from the chest wall, followed by their attachment to the or another graft proximally and to the target coronary distally via end-to-side . This revascularization targets stenotic segments, particularly in the left anterior descending (LAD), circumflex, or right coronary arteries, to alleviate ischemia and prevent . The saphenous vein is harvested endoscopically or via open incision along the leg, often as a reversed graft to minimize valve-related flow obstruction, while the IMA—preferred for its superior endothelial function and resistance to —is mobilized skeletonized or pedicled from the chest, preserving surrounding veins for collateral flow. employs fine sutures (7-0 to 8-0) to connect the graft to a longitudinal arteriotomy in the beyond the , ensuring a tension-free, hemostatic union under ; proximal to the uses partial occlusion clamps for vein grafts or is end-to-end for sequential arterial configurations. CABG is indicated primarily for patients with multivessel (CAD) where (PCI) is unsuitable due to complex anatomy, such as high SYNTAX scores (>33), diffuse , or left main involvement, particularly in those with or reduced , as it offers improved long-term survival over PCI in these cohorts. CABG can be performed using on-pump or off-pump techniques, with the latter avoiding (CPB) to stabilize the heart, thereby eliminating bypass-related inflammatory responses and reducing operative time associated with CPB setup and weaning. In on-pump CABG, arrests the heart during on a non-beating field, facilitating precise , whereas off-pump (also called "beating heart") uses stabilizers and intracoronary shunts to maintain visibility and flow, potentially lowering risks of , renal dysfunction, and transfusion needs in high-risk patients. Long-term outcomes favor arterial conduits like the IMA, with patency rates exceeding 90% at 10 years due to their vasoreactivity and reduced intimal compared to grafts, which occlude in up to 50% by the same interval.

Valve Repair and Replacement

Valve repair and replacement are critical interventions in cardiothoracic surgery aimed at restoring normal function in patients with , which can involve (narrowing) or regurgitation (leakage). These procedures are typically performed via open-heart using , though minimally invasive approaches may be referenced for context in select cases. Repair is preferred over replacement when feasible, as it preserves native tissue and avoids the need for lifelong anticoagulation in many instances. Common repair techniques address specific pathologies, such as , where annuloplasty reinforces the annulus by implanting a ring to improve leaflet coaptation and reduce leakage. This method is often combined with leaflet resection or chordal replacement using materials like to enhance durability. For valvular , particularly caused by rheumatic heart disease, commissurotomy separates fused commissures of the valve leaflets to restore adequate opening and blood flow. These repairs yield favorable long-term outcomes, with annuloplasty demonstrating comparable five-year efficacy to other methods in . When repair is not possible due to extensive damage, is indicated, utilizing either mechanical or bioprosthetic prostheses. Mechanical valves, such as bileaflet designs, offer superior durability and are constructed from materials like to mimic native valve motion with low thrombogenicity. Bioprosthetic valves, derived from animal or porcine tissue, provide hemodynamic performance similar to native valves but degenerate over time, typically lasting 10-15 years. The , specifically for , relocates the patient's pulmonary autograft to the aortic position and replaces the with a homograft, achieving survival rates equivalent to the general population in young adults under 50. Indications for surgery differ by valve: aortic valve interventions are often prompted by severe stenosis or regurgitation leading to heart failure, while mitral procedures address similar dysfunction or annular dilation. is a frequent cause, necessitating urgent for severe valve destruction, abscess formation, or uncontrolled , with aortic and mitral valves commonly affected. Post-replacement anticoagulation is mandatory for mechanical valves to prevent ; is standard, targeting an international normalized ratio (INR) of 2.0-3.0 for aortic positions without additional risk factors and 2.5-3.5 for mitral or multiple valves. Bioprosthetic valves generally do not require long-term anticoagulation unless or other risks are present, reducing bleeding complications compared to mechanical options.

Congenital Defect Correction

Congenital defect correction in cardiothoracic surgery primarily addresses structural heart anomalies present at birth, most commonly in pediatric patients, to restore normal and prevent long-term complications such as or . These procedures often involve open-heart techniques under , though minimally invasive and transcatheter options have become standard for select defects. Surgical intervention timing depends on the defect's severity, with repairs typically performed in infancy or to optimize growth and function. Atrial septal defect (ASD) closure corrects a persistent opening between the left and right atria, which can lead to right ventricular if untreated. Surgical repair traditionally uses a pericardial or synthetic patch sutured via to close the defect, providing direct visualization and allowing concomitant procedures if needed. Alternatively, transcatheter closure employs devices like the Amplatzer septal occluder, deployed through a to occlude the defect percutaneously, offering reduced recovery time and lower complication rates in suitable pediatric candidates. Both approaches achieve high success rates, with closure in over 95% of cases. Tetralogy of Fallot repair addresses the combination of , pulmonary stenosis, , and , which causes . The procedure, typically performed between 3 and 6 months of age, involves a transatrial or transventricular approach to patch the ventricular septal defect with prosthetic material and reconstruct the pulmonary outflow tract, often using a transannular patch to relieve obstruction and improve pulmonary blood flow. This comprehensive correction aims to eliminate shunting and restore biventricular physiology. In cases of severe , preliminary palliative shunts like the Blalock-Taussig procedure—first described in —may be used to increase pulmonary flow prior to complete repair. For complex defects like (HLHS), correction follows a multistage palliation to support systemic circulation with a single functional ventricle. Stage 1, the , performed in neonates, reconstructs the hypoplastic aorta using the main pulmonary artery as a neoaorta, augments the , and ensures pulmonary blood flow via a modified Blalock-Taussig shunt or right ventricle-to-pulmonary artery conduit, all under . This initial surgery stabilizes the infant for subsequent stages, such as the Glenn and Fontan procedures, to progressively redirect venous return. Long-term outcomes for repair of simple congenital defects, such as isolated ASD or ventricular septal defects, exceed 95% survival into adulthood, approaching rates in the general population with minimal late morbidity when performed early. For more complex repairs like , 20-year survival post-repair reaches 94.5%, though reinterventions for residual issues may be required in up to 40% of cases. HLHS staging yields lower early survival of 70-80% after Norwood stage 1, but overall transplant-free survival improves to over 70% at 5 years with modern protocols.

Transplantation and Assist Devices

Heart transplantation serves as a definitive treatment for patients with end-stage who have exhausted other medical and surgical options, replacing the recipient's failing heart with a donor organ to restore cardiac function. The orthotopic heart transplant procedure involves recipient cardiectomy, where the diseased heart is excised while preserving the posterior left atrial wall and vena cavae, followed by implantation of the donor heart using the bicaval technique. This technique connects the donor and recipient superior and inferior vena cavae end-to-end, along with separate pulmonary venous and aortic , minimizing atrial dysrhythmias and optimizing compared to earlier biatrial methods. For patients awaiting transplantation or ineligible due to donor shortages, ventricular assist devices (VADs) provide mechanical circulatory support as a bridge-to-transplant or destination . Left ventricular assist devices (LVADs), such as continuous-flow models, unload the failing left ventricle by pumping blood from the left ventricle to the , improving organ perfusion and while bridging patients to transplant. In destination therapy, LVADs serve as a long-term alternative for non-transplant candidates, with outcomes showing 1-year survival rates exceeding 80% in contemporary devices. Post-transplant management relies on to prevent rejection, typically involving triple therapy with inhibitors (e.g., ), corticosteroids, and antimetabolites (e.g., mycophenolate mofetil). This regimen targets T-cell activation and proliferation, balancing rejection risk against infection and malignancy, with protocols often including induction therapy for high-risk patients. Survival following heart transplantation has improved with advancements in donor selection and perioperative care; according to the International Society for Heart and Lung Transplantation (ISHLT) Registry, 1-year post-transplant is approximately 85%, while 5-year reaches about 75% in recent cohorts. These rates reflect conditional benefits, with half-life expectancy now exceeding 12 years for recipients surviving the first year.

Minimally Invasive Approaches

Minimally invasive approaches in cardiac surgery aim to reduce surgical trauma by employing smaller incisions and advanced visualization tools, thereby improving patient recovery while maintaining efficacy comparable to traditional open techniques. (VATS) has emerged as a key method for repairing atrial septal defects (ASDs), particularly secundum-type defects, where a small right anterior incision (typically 3-5 cm) allows for the insertion of a thoracoscope and specialized instruments to close the defect under direct visualization with . This technique avoids full sternotomy, enabling precise patch or direct suture closure with minimal disruption to surrounding structures. Similarly, VATS facilitates through port-access approaches, involving multiple small intercostal incisions for endoscopic guidance, which supports leaflet resection, annuloplasty, or neochord implantation while preserving valve tissue and function. Robotic-assisted surgery, utilizing systems like the , further refines these minimally invasive strategies for procedures such as coronary artery bypass grafting (CABG) and valve interventions. In robotic CABG, the left internal mammary artery is harvested endoscopically through ports on the chest wall, followed by to the on a beating heart, all controlled via a console that provides three-dimensional magnified views and tremor-filtered precision. This approach has been applied successfully in multivessel disease, reducing the need for larger incisions. For valve surgery, robotic platforms enable through right mini-thoracotomy ports, achieving repair rates exceeding 95% with enhanced dexterity for complex reconstructions. The , approved by the FDA for cardiac procedures since 2000, has been instrumental in over 10,000 such operations globally, demonstrating feasibility and safety. Hybrid procedures integrate (PCI) with surgical grafting to optimize in complex coronary disease, often combining minimally invasive CABG for the with stenting of non-bypassable vessels. Performed sequentially in a , this strategy leverages the durability of surgical grafts with the immediacy of PCI, typically involving robotic or mini-thoracotomy access for the surgical component. Clinical outcomes indicate equivalent patency rates to conventional CABG at one year, with reduced overall invasiveness. These approaches collectively offer significant benefits, including smaller incision sizes (2-6 cm versus 20-25 cm in sternotomy), which correlate with lower postoperative pain and faster . Hospital stays are notably shorter, averaging 3-5 days compared to 7-10 days for open surgery, facilitating earlier discharge and rehabilitation. Additionally, the reduced tissue disruption lowers deep sternal wound rates to under 1%, versus 2-5% in traditional methods, while maintaining low mortality (1-2%) and stroke incidence. Long-term durability mirrors open procedures, with hybrid and robotic techniques showing graft patency above 90% at five years in select cohorts.

Thoracic Surgery

Pulmonary Resections

Pulmonary resections encompass the surgical excision of tissue, most commonly performed to treat non-small cell (NSCLC) or other parenchymal diseases such as infections or benign tumors. These procedures aim to achieve complete tumor removal while preserving as much functional tissue as possible to maintain postoperative respiratory capacity. The choice of resection type depends on tumor location, size, stage, and comorbidities, with techniques evolving from traditional open approaches to minimally invasive methods that reduce recovery time and complications. Lobectomy, the removal of an entire pulmonary lobe, remains the standard curative resection for early-stage NSCLC involving peripheral tumors, offering oncologic equivalence to more extensive procedures in select cases. Segmentectomy, by contrast, targets one or more bronchopulmonary segments, conserving greater volume and benefiting patients with limited reserve or small tumors less than 2 cm in diameter. Both can be executed via posterolateral , an open incision along the chest wall providing direct visualization, or (VATS), which utilizes 2–4 small ports for instruments and a camera to minimize trauma. In VATS , the hilum is typically dissected first, ligating vascular and bronchial structures before lobe extraction, with three incisions being the most common configuration. For segmentectomy under VATS, the process often starts with segmental vein isolation, followed by arterial and bronchial division, guided by preoperative imaging to delineate intersegmental planes. These thoracoscopic approaches have demonstrated lower postoperative pain, shorter hospital stays, and comparable long-term survival to , particularly for stage I disease. Pneumonectomy, the total extirpation of one , is reserved for centrally located tumors encroaching on the main , , or hilum, where partial resections like sleeve lobectomy are infeasible due to anatomical constraints. This procedure, performed exclusively through , involves sequential ligation and division of the ipsilateral , veins, and mainstem , followed by meticulous closure to prevent postpneumonectomy . Despite its curative potential in advanced central NSCLC, pneumonectomy carries higher perioperative risks, including cardiac strain and , with 30-day mortality rates around 5–10% in modern series. Lymph node dissection during pulmonary resections is essential for accurate pathologic staging in , influencing decisions. Lymph node sampling selectively removes suspicious nodes identified by preoperative or intraoperative , offering a less invasive option for staging without comprehensive exploration. Systematic mediastinal lymph node dissection, however, entails en bloc removal of all accessible ipsilateral hilar and mediastinal stations (levels 2–9 per the International Association for the Study of Lung Cancer map), providing superior nodal yield—often three times that of sampling—and more precise N-status determination. While systematic dissection enhances staging accuracy, randomized trials show no consistent overall advantage over sampling in early-stage , though it may benefit higher-risk patients by reducing occult understaging. Eligibility for pulmonary resection hinges on preoperative cardiopulmonary assessment to predict postoperative function and mitigate risks. The key metric is the predicted postoperative forced expiratory volume in 1 second (ppoFEV1), calculated by subtracting the contribution of resected segments from preoperative values using perfusion or segment-count formulas. A ppoFEV1 exceeding 40% of age-, -, and height-adjusted predicted normal is widely accepted as a threshold for low-risk resection across , segmentectomy, or , correlating with reduced postoperative dyspnea and mortality below 5%. Patients with borderline values (30–40% predicted) may require further exercise testing, such as shuttle walk or stair climb, to confirm tolerance.

Esophageal Procedures

Esophageal procedures in cardiothoracic surgery primarily address malignancies, benign disorders, and functional issues within the esophagus, often requiring precise thoracic access and reconstruction to restore swallowing and prevent complications like reflux. These interventions, performed by thoracic surgeons, target conditions such as esophageal cancer and gastroesophageal reflux disease (GERD), where multidisciplinary staging involving gastroenterology ensures optimal patient selection. Esophagectomy remains a cornerstone for treating mid- and distal esophageal cancers, with the Ivor Lewis approach being a transthoracic variant that involves an abdominal incision for gastric mobilization followed by a right to resect the esophagus and create an intrathoracic esophagogastric . This two-stage procedure facilitates en bloc resection of the tumor while preserving a gastric conduit for reconstruction, typically via gastric pull-up, where the is elevated and anastomosed to the proximal . The Ivor Lewis method is particularly suited for mid-esophageal lesions, offering improved clearance compared to transhiatal alternatives, though it carries risks of pulmonary complications due to . Minimally invasive esophagectomy (MIE) has emerged as a preferred technique to mitigate the morbidity of open procedures, employing and to perform the Ivor Lewis approach with reduced tissue trauma. In MIE, the is mobilized through small incisions, and the gastric conduit is pulled up via endoscopy-assisted , leading to shorter hospital stays, lower rates of injury, and a as low as 0.9% in experienced centers. This evolution, supported by high-volume studies, demonstrates decreased postoperative and overall complications without compromising oncologic outcomes. For benign conditions like severe GERD unresponsive to medical therapy, anti-reflux surgeries such as reinforce the lower esophageal sphincter by laparoscopically wrapping the gastric fundus 360 degrees around the distal , effectively preventing acid reflux. This procedure, often combined with hiatal hernia repair, achieves symptom resolution in over 90% of patients at long-term follow-up and is a standard thoracic intervention due to its minimally invasive nature and low recurrence rates. Esophageal reconstruction following esophagectomy prioritizes conduit selection to ensure durable function, with gastric pull-up serving as the primary method due to its reliable vascular supply and simplicity in mobilizing the as a tubular graft. In cases where the is unavailable—such as prior —colon interposition offers a viable alternative, utilizing a segment of transverse or left colon routed retrosternally or intrathoracically to bridge the esophageal defect. Comparative studies indicate that colonic grafts yield superior functional outcomes, including zero regurgitation rates and higher patient satisfaction, compared to gastric pull-up, which may experience in up to 66% of cases with pyloric drainage.

Volume Reduction and Transplants

Lung volume reduction surgery (LVRS) is a palliative procedure designed to alleviate symptoms in patients with severe chronic obstructive pulmonary disease (COPD), particularly emphysema, by excising hyperinflated, poorly functioning lung tissue to allow healthier regions to expand and improve ventilation. The surgery typically involves the resection of 20% to 35% of the most damaged lung parenchyma, often targeting bullous or heterogeneous emphysematous areas through video-assisted thoracoscopic surgery (VATS) or, less commonly, median sternotomy for bilateral procedures. This approach reduces thoracic hyperinflation, enhances diaphragmatic mechanics, and boosts overall respiratory efficiency, with candidates selected based on criteria such as forced expiratory volume in one second (FEV1) below 45% predicted, residual volume exceeding 150% predicted, and preserved perfusion in non-resected areas. Indications for LVRS are strictly limited to patients with advanced, heterogeneous emphysema who remain symptomatic despite optimal medical therapy, including those ineligible for or unresponsive to bronchodilators, pulmonary rehabilitation, and smoking cessation. The National Emphysema Treatment Trial (NETT) established that LVRS confers survival benefits and improved quality of life in subsets with upper-lobe predominant emphysema and low exercise capacity post-rehabilitation, though it carries perioperative risks like prolonged air leaks or pneumonia, with 90-day mortality around 5-7% in high-risk groups. Long-term outcomes show sustained functional gains, such as a 20-30% increase in FEV1 and six-minute walk distance, persisting up to five years in responders, underscoring its role as a bridge to potential lung transplantation. Lung transplantation represents the definitive treatment for end-stage lung disease, involving the replacement of one or both lungs to restore in patients with irreversible conditions like (IPF) or . Single-lung transplantation is preferred for IPF due to better donor-recipient size matching and preservation of cardiac function, while double-lung (bilateral sequential) transplantation is favored for or to eliminate bilateral disease and reduce infection risks. The surgical technique emphasizes precise bronchial using running or interrupted sutures to maintain airway patency, often with telescoping or end-to-end configurations, alongside vascular anastomoses to the and left atrium; is selectively employed for hemodynamic instability. Post-transplant management focuses on to prevent rejection, with median for double-lung recipients reaching 5.8 years, influenced by factors like donor quality and early complications such as primary graft dysfunction. One-year exceeds 80%, but chronic allograft vasculopathy and infections remain challenges, with bilateral procedures showing superior long-term pulmonary function over single-lung transplants in non-fibrotic diseases. Selection criteria, guided by the Lung Allocation Score, prioritize urgency for IPF patients with rapid decline (median untreated 2-3 years) and alpha-1 cases with preserved nutritional status.

Mediastinal Interventions

Mediastinal interventions in cardiothoracic surgery address pathologies within the central thoracic compartment, including masses, infections, and vascular abnormalities that can compromise vital structures such as the thymus, lymph nodes, and aorta. These procedures aim to diagnose, resect, or repair mediastinal issues while minimizing risks to adjacent organs like the heart and great vessels. Common approaches range from open techniques like median sternotomy to minimally invasive options such as video-assisted thoracoscopic surgery (VATS) and endovascular methods, selected based on the lesion's location, size, and patient comorbidities. Outcomes have improved with advancements in imaging and perioperative care, though challenges like infection control and anatomical complexity persist. Thymectomy, the surgical removal of the gland, is a cornerstone intervention for (MG) and , conditions where the plays a pathogenic role in or neoplastic growth. In non-thymomatous MG, induces remission or reduces medication needs in up to 40-50% of patients, with benefits most pronounced in early-onset cases, as evidenced by long-term follow-up studies. For thymoma-associated MG, complete resection is essential for oncologic control, achieving 5-year survival rates exceeding 90% for early-stage tumors when margins are clear. Surgical approaches include the traditional , which provides wide exposure for en bloc resection of the and surrounding mediastinal fat, ensuring radical removal in 95% of cases. Minimally invasive alternatives, such as VATS or robotic-assisted , offer comparable oncologic efficacy with reduced postoperative pain, shorter hospital stays (median 3-5 days versus 7-10 days for open ), and lower complication rates (e.g., 5-10% vs. 15-20%), particularly suitable for stage I-II thymomas under 4 cm. These techniques involve multiple ports for dissection under thoracoscopic guidance, preserving sternal integrity and improving . Complications, including injury (2-5%) and bleeding, are mitigated by preoperative imaging like CT or MRI to delineate . Mediastinoscopy serves as a diagnostic tool for biopsy of mediastinal lymph nodes, primarily in staging lung cancer or evaluating unexplained lymphadenopathy. Performed under general anesthesia via a small suprasternal incision, a rigid scope is advanced along the pretracheal plane to access paratracheal (stations 2R/2L, 4R/4L) and subcarinal (station 7) nodes, allowing targeted sampling with forceps for histopathologic analysis. This procedure yields diagnostic accuracy of 85-95% for malignancy, superior to imaging alone, and is particularly valuable when endobronchial ultrasound (EBUS) is inconclusive, providing whole-node retrieval for comprehensive staging. In thoracic surgery, it guides decisions on resectability, with false-negative rates below 10% in experienced hands. Risks are low, including hoarseness (1-2% from recurrent laryngeal nerve irritation) and hemorrhage (0.5-1%), and it remains a gold standard despite emerging alternatives like EBUS-TBNA, due to its ability to sample anterior mediastinal structures inaccessible by bronchoscopy. Management of descending aortic aneurysms often involves thoracic endovascular aortic repair (), a less invasive alternative to open surgery for aneurysms involving the distal or descending . Indicated for aneurysms exceeding 5.5 cm in diameter or those with rapid growth (>0.5 cm/year), deploys a stent-graft via femoral access under fluoroscopic guidance to exclude the aneurysmal sac from systemic pressure, promoting and remodeling. Compared to open repair, reduces (2-5% vs. 5-10%) and risk (3-7% vs. 8-15%), with faster recovery (hospital stay 4-7 days) and suitability for high-risk patients. The Society for guidelines endorse as first-line for anatomically suitable descending aneurysms, emphasizing proximal and distal zones of at least 15-20 mm for seal. Long-term durability is supported by 5-year rates of 70-80%, though surveillance for endoleaks (type I/II) is required via serial CT . Complications like (2-4%) arise from wire manipulation near the arch, underscoring the need for hybrid approaches in complex cases. Post-sternotomy mediastinitis, a severe complication following cardiac surgery (incidence 1-5%), necessitates prompt drainage and debridement to control infection and prevent sepsis. Deep sternal wound infections involve mediastinal contamination by organisms like Staphylococcus aureus, managed initially with broad-spectrum antibiotics guided by cultures. Surgical intervention includes reopening the sternotomy, aggressive debridement of necrotic tissue, and irrigation, often followed by vacuum-assisted closure (VAC) therapy to promote granulation and reduce bacterial load. VAC applies subatmospheric pressure via a sealed foam dressing, achieving wound closure success in 80-90% of cases and lowering reoperation rates compared to continuous irrigation alone. For extensive defects, reconstruction with omental or muscle flaps (e.g., pectoralis major) provides vascularized coverage, improving survival from historical 20-40% to 85-95% in modern series. Early intervention within 48 hours of diagnosis is critical, as delays correlate with higher mortality.

Risks and Outcomes

Perioperative Risks

Cardiothoracic surgery, encompassing both cardiac and thoracic procedures, carries inherent perioperative risks that can lead to significant morbidity and mortality. Common complications include excessive , infections, and arrhythmias. Postoperative often necessitates re-exploration, occurring in approximately 2-5% of cases, with rates varying based on procedural complexity and factors. Deep sternal wound infections, a serious infectious complication, affect 1-2% of patients undergoing , contributing to prolonged hospital stays and higher mortality. Arrhythmias, particularly postoperative , are frequent, with incidences ranging from 20-40% in cardiac procedures, increasing the risk of hemodynamic instability and . Patient-specific factors substantially influence perioperative outcomes. Advanced age greater than 70 years is associated with a 2- to 5-fold increase in mortality risk in frail elderly patients compared to younger patients, due to reduced physiological reserve and higher burden. elevates the risk of deep sternal wound infections, with affected patients facing up to twice the incidence compared to non-obese individuals, exacerbated by impaired and . Intraoperative elements, such as the duration of (CPB), also play a critical role. Prolonged CPB times exceeding 120 minutes are linked to a higher incidence of , occurring in up to 30% of such cases, through mechanisms including and renal hypoperfusion. Overall, mortality rates for elective cardiac surgeries range from 1-3%, reflecting advances in perioperative management, while thoracic procedures generally carry risks at 1-3% as of 2024 per STS data, influenced by the extent of resection and underlying pulmonary disease. Specific procedure-related risks, such as those in coronary artery bypass grafting or , may compound these general hazards but are addressed in dedicated sections.

Cardiac-Specific Complications

One of the primary cardiac-specific complications in coronary artery bypass grafting (CABG) is perioperative , with an incidence of approximately 1-3% among patients undergoing the procedure. This risk is primarily attributed to embolic events arising from aortic manipulation during cannulation or clamping, as well as microemboli released during . Strategies to mitigate this include off-pump techniques or minimized aortic contact to reduce manipulation-related emboli. Low syndrome (LCOS) represents a significant postoperative complication following cardiac , characterized by inadequate cardiac pump function leading to tissue hypoperfusion and hypoxia. It typically manifests within the first 24-48 hours post-bypass and requires prompt intervention with inotropic agents such as or to enhance , or mechanical support via (IABP) to augment coronary and reduce when pharmacological measures prove insufficient. In coronary procedures, early graft failure due to remains a concern, though its incidence is substantially reduced to less than 10% within the first year with perioperative antiplatelet , such as aspirin or dual antiplatelet regimens. predominantly occurs in the initial postoperative week, often linked to endothelial injury during harvesting or , and is effectively prevented by maintaining therapeutic antiplatelet levels to inhibit platelet aggregation and promote graft patency. Recurrence of after valve surgery poses a long-term cardiac-specific , with cumulative incidence rates ranging from 3% to 9% within 5 years, depending on prosthesis type and patient factors like ongoing intravenous drug use. This complication arises from persistent bacteremia or prosthetic material , necessitating lifelong prophylaxis and close to detect reinfection early and avoid reoperation.

Thoracic-Specific Complications

Thoracic-specific complications in cardiothoracic surgery primarily arise from disruptions in pulmonary, pleural, or esophageal integrity, often leading to significant morbidity if not promptly addressed. These issues are distinct from general perioperative risks, such as infections, which may compound but are managed separately. Prolonged air leak, defined as persistent leakage from the beyond five to seven days post-resection, occurs in approximately 10-15% of patients following and can result in prolonged , necessitating drainage or additional interventions. This complication is the most common after pulmonary resections, with an incidence of 14.7% in one cohort of patients undergoing (VATS) lobectomies, often linked to underlying or incomplete fissure sealing during surgery. typically involves conservative measures like low-pressure on s, with surgical options such as or sealants used prophylactically in high-risk cases to reduce duration and stay. Chylothorax, characterized by accumulation of lymphatic fluid in the pleural space due to injury, is a notable complication after esophageal or mediastinal surgeries, with an incidence of 1-4% following esophagectomy. Initial management focuses on conservative strategies, including pleural drainage to evacuate the and administration of , a somatostatin analog that reduces lymphatic flow by inhibiting secretion, achieving resolution in up to 70% of cases without surgical intervention. If drainage exceeds 500-1000 mL/day persistently, ligation or may be required to prevent nutritional deficits and immune compromise. Respiratory failure requiring is more prevalent after extensive resections like , affecting up to 20% of patients due to reduced pulmonary reserve and ventilation-perfusion mismatches. In a study of 170 cases, 18% developed postoperative necessitating prolonged ventilation or reintubation, often triggered by intraoperative factors such as high tidal volumes or underlying . Outcomes are guarded, with increased 30-day mortality, emphasizing the need for meticulous perioperative lung protection strategies, including protective ventilation and early mobilization. Anastomotic leak following esophagectomy, occurring in 5-10% of cases with intrathoracic anastomoses, represents a critical thoracic complication that can lead to mediastinitis and , elevating mortality to 30-60%. This leakage from the esophageal-gastric conduit junction often manifests within 7-10 days postoperatively, detected via contrast studies or , and requires urgent drainage, antibiotics, and sometimes reoperation or stenting to mitigate septic sequelae. Early recognition through routine monitoring is essential, as leaks contribute disproportionately to prolonged intensive care stays and long-term quality-of-life impairments. Recent data from the Society of Thoracic Surgeons (STS) National Database as of 2024 indicate operative mortality rates of 1.1% for general thoracic procedures, reflecting ongoing improvements in outcomes.

References

Add your contribution
Related Hubs
User Avatar
No comments yet.